InvestorsHub Logo
Followers 19
Posts 1896
Boards Moderated 0
Alias Born 02/10/2014

Re: Bob_the_Trader post# 12712

Thursday, 05/08/2014 11:31:22 AM

Thursday, May 08, 2014 11:31:22 AM

Post# of 48316
Haha. I don't think you can compare the two types of partnerships. Aegnus' was a license agreement at 100 million to make MK-3475 better but not a new standard of care. ONCS' deal I believe will be much more lucrative and has the potential to set a new standard of care and, at the same time, by-pass a phase 3 trial in at least melanoma.